Clinical Trials Logo

Metastatic Solid Tumors clinical trials

View clinical trials related to Metastatic Solid Tumors.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06031441 Recruiting - Clinical trials for Metastatic Solid Tumors

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

Start date: November 27, 2023
Phase: Phase 1
Study type: Interventional

This is a first-in-human Phase I, open-label, dose-escalation and expansion study designed to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, pharmacodynamic, and preliminary anti-tumor activity of RO7566802 as a single agent and in combination with atezolizumab in participants with locally advanced, recurrent, or metastatic incurable solid tumor malignancies. Participants will be enrolled in 2 stages: dose escalation and expansion.

NCT ID: NCT05853367 Recruiting - Clinical trials for Advanced Solid Tumors

Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001)

Start date: July 6, 2023
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the efficacy, safety, and tolerability of MK-0472 administered as monotherapy and in combination with pembrolizumab (MK-3475) or MK-1084 in participants with histologically or cytologically confirmed diagnosis of advanced/metastatic solid tumors.

NCT ID: NCT05836324 Recruiting - Solid Tumors Clinical Trials

A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors

Start date: July 24, 2023
Phase: Phase 1
Study type: Interventional

To evaluate the safety, tolerability, and DLTs and determine the MTD and/or RDE(s) of INCA33890 in participants with select advanced or metastatic solid tumors.

NCT ID: NCT05605496 Recruiting - Clinical trials for Advanced Solid Tumors

NP137 Clinical and Biological Activities Assessment in Patients With Advanced/Metastatic Solid Tumors Treated by Standard Anti PD-1/PD-L1 Immunotherapies

IMMUNONET
Start date: January 6, 2023
Phase: Phase 2
Study type: Interventional

This study is a multicenter, open-label, proof-of-concept study aiming to assess the clinical and biological impact of NP137 when added to standard PD-1/PD-L1 blockade therapy in 3 independent cohorts of advanced or metastatic solid tumors with various sensitivity to anti-PD-1/PD-L1: - Cohort 1 [Stable Disease]: Patients with a radiological documentation of SD according to RECIST V1.1 criteria following at least 12 weeks under standard anti PD-1/PD-L1 therapy. - Cohort 2 [primary refractory]: Patients with documented radiological PD according to RECIST V1.1 but with clinical benefit under anti PD-1/PD-L1 standard therapy. - Cohort 3 [secondary refractory]: Patients with documented radiological PD following an initial Objective Response according to RECIST V1.1, with clinical benefit under standard anti-PD-1/PD-L1.

NCT ID: NCT05494918 Recruiting - Clinical trials for Advanced Solid Tumors

First-In-Human Study in Subjects With Advanced or Metastatic Solid Malignant Tumors

Start date: September 2, 2022
Phase: Phase 1
Study type: Interventional

This study is an open-label, multicenter, first-in-human, Phase I, dose escalation study to evaluate the safety, tolerability, PK, and preliminary anti-tumor activity of JSKN003 in subjects with advanced inoperable or metastatic solid malignant tumors that are expected to be HER2 expression.

NCT ID: NCT05487235 Recruiting - Clinical trials for Advanced Solid Tumors

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

Start date: August 17, 2022
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and activity of GDC-1971 when administered in combination with atezolizumab in participants with locally advanced or metastatic solid tumors. The study will have 2 stages- dose finding stage and expansion stage. In expansion stage participants with non-small cell lung cancer programmed death ligand -1 high (NSCLC PD L-1 high), NSCLC PD L-1 low, head and neck squamous cell carcinoma (HNSCC) PD L-1 positive, BRAF wild type (BRAF WT) melanoma and any locally advanced or metastatic solid tumors will be enrolled.

NCT ID: NCT04094610 Recruiting - Lymphoma Clinical Trials

A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

Start date: March 12, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

Phase 1 will evaluate the safety and tolerability at different dose levels of repotrectinib in pediatric and young adult subjects with advanced or metastatic malignancies harboring anaplastic lymphoma kinase (ALK), receptor tyrosine kinase encoded by the gene ROS1 (ROS1), or neurotrophic receptor kinase genes encoding TRK kinase family (NTRK1-3) alterations to estimate the Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) and select the Pediatric Recommended Phase 2 Dose (RP2D). Phase 2 will determine the anti-tumor activity of repotrectinib in pediatric and young adult subjects with advanced or metastatic malignancies harboring ROS1 or NTRK1-3 alterations.

NCT ID: NCT03809624 Recruiting - Clinical trials for Non-small Cell Lung Cancer

Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer

PDL1x41BB
Start date: January 30, 2019
Phase: Phase 2
Study type: Interventional

This is a first-in-human, open-label, nonrandomized, four-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX-105 and INBRX-105 in combination with Pembrolizumab. INBRX-105, a next generation bispecific antibody, targets the human programmed death-ligand 1 (PD-L1) receptor and the human 4-1BB receptor. INBRX-105 provides localized conditional T-cell co-stimulation through 4-1BB agonism.

NCT ID: NCT03646071 Recruiting - Clinical trials for Metastatic Solid Tumors

A Study of RX108 in Patients With Locally Advanced or Metastatic Solid Tumors

Start date: August 1, 2018
Phase: Phase 1
Study type: Interventional

RX108 is a novel, potent, small-molecule inhibitor of Na+/K+-ATPase. The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK) and efficacy of RX108 in patients with locally advanced or metastatic solid tumors.

NCT ID: NCT03388632 Recruiting - Clinical trials for Metastatic Solid Tumors

Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers

Start date: February 5, 2018
Phase: Phase 1
Study type: Interventional

Background: The drug IL-15 activates the immune system. The drugs nivolumab and ipilimumab unblock immune cells. The drugs together may allow immune cells to recognize and attack cancer cells, causing tumors to shrink. Objective: To test the effects and maximum dose of IL-15, nivolumab, and ipilimumab. Eligibility: People ages 18 and older who have cancer that does not respond to treatment Design: Participants will be screened with: - Medical history - Physical exam - Heart, blood, and urine tests - Scans Tumor biopsy: A small needle removes a tumor sample. Participants will be in 1 of 3 treatment groups: - IL-15 with nivolumab - IL-15 with ipilimumab - IL-15 with nivolumab and ipilimumab Participants will take the drugs in four 6-week cycles. IL-15 is injected under the skin. The other two drugs are injected into an arm vein over 60-90 minutes. Participants may need to stay at the hospital 2-3 hours after the first dose of any drug to watch for side effects. Each cycle will include: - Weekly blood and urine tests - 5 IL-15 injections - 1 ipilimumab injection if applicable - 3 nivolumab injections if applicable - Scans and a tumor biopsy on day 42 After cycle 4, participants will stop taking IL-15. They will continue the other drugs until they can no longer tolerate the side effects or their cancer gets worse. Those cycles will include: - Blood tests on 3-4 days - Urine tests on 1 day - 1 ipilimumab injection if applicable - 3 nivolumab injections if applicable - Scans every other cycle After participants stop treatment, their doctor will monitor their side effects for 4 months or until they go away.